Business Context and Reporting Period
This Form 8-K is filed by Aziyo Biologics, Inc. (trading symbol: AZYO) on December 30, 2021. The report addresses a listing deficiency notice received from The Nasdaq Stock Market regarding the company's stockholders' equity.
Key Financial Metrics
- Equity Offering Proceeds: The company closed an equity offering on December 8, 2021, receiving gross proceeds of approximately $14.0 million before deducting offering expenses.
- Stockholders' Equity: As of the September 30, 2021 quarter, equity was below the $10.0 million threshold required by Nasdaq Listing Rule 5450(b)(1)(A). The filing does not provide a specific updated equity figure as of December 30, 2021, but states the offering is expected to restore compliance.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or margins for the current period.
- Debt and Liquidity: Specific debt levels and liquidity ratios are not disclosed in this document.
Material Changes
The primary material change is the receipt of approximately $14.0 million in gross proceeds from an equity offering closed on December 8, 2021. This capital raise was executed specifically to address the deficiency in stockholders' equity that triggered a delisting warning from Nasdaq on November 16, 2021.
Outlook, Risks, and Management Commentary
- Compliance Status: Management expects to receive a notice of conditional compliance from Nasdaq following this filing. Final confirmation of compliance is expected after the filing of the Annual Report on Form 10-K for the year ended December 31, 2021.
- Forward-Looking Statements: The company notes that financial results discussed are preliminary. Actual results may differ materially due to year-end accounting procedures, internal control adjustments, and audit processes.
- Risks: The filing references risk factors detailed in the November 10, 2021 Form 10-Q, warning that actual results may differ from projections and that the company undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the final audited stockholders' equity figure in the upcoming Form 10-K for the year ended December 31, 2021.
- Confirm the official notice of compliance from Nasdaq following the 10-K filing.
- Review the November 10, 2021 Form 10-Q for detailed risk factors and prior financial performance.
- Monitor for any adjustments to the $14.0 million gross proceeds figure once offering expenses are finalized in the audited statements.